SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

The World Cup warning: Riots don’t start in the streets. They start online

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

1

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

2

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

3

Echo: “Employees have become very good at identifying performative culture”

4

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

5

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

PhaseV

4 stories about PhaseV

Promising HealthTech

WATCH: CTech's most promising healthtech startups

Here's everything you need to know about Sensi.ai, Briya Labs, PhaseV, Zorro, and DeepCure

כנס ניו יורק - ד"ר רביב פרילוק מנכ"ל PhaseV

PhaseV raises $50 million Series A to rethink how drugs get to market

With over 30 global customers, the AI startup targets inefficiencies in clinical trials.

CTech NY Conference Dr Raviv Pryluk

Here’s how PhaseV uses AI to optimize clinical trials to speed clinical development

27.03.25|James Spiro

CEO and Co-Founder Dr. Raviv Pryluk spoke to CTech after being named as one of the Top 10 Israeli startups to watch out for in 2025 at Calcalist’s Mind The Tech conference in New York.

Raviv Pryluk PhaseV

PhaseV raises $15 million to optimize clinical trials with causal machine learning

The Israeli startup detects hidden signals in clinical data and extracts actionable insights for planning the next steps